Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Saborowski

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Hepatology Communications|March 13, 2019
Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer <i>In</i> <i>Vivo</i> and <i>In Vitro</i>Anna Saborowski, Katharina Wolff, Steffi Spielberg, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2026
Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 studyArndt Vogel, Najib Ben Khaled, Javier Ruiz Ramirez, et al.
Therapeutic Advances in Medical Oncology|March 7, 2022
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experienceTiago de Castro, Leonie S Jochheim, Melanie Bathon, et al.
Clinical Transplantation|May 19, 2026
A Retrospective Multicenter Study Identifies a Similar Overall Survival of Patients After Liver Transplantation With Incidental Cholangiocarcinoma Compared to Hepatocellular CarcinomaSophia Heinrich, Alejandro Campos-Murguia, Angelina Mensah, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trialArndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
Gut|November 27, 2019
Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cellsZhen Dai, Guangqi Song, Asha Balakrishnan, et al.
JHEP Reports : Innovation in Hepatology|June 18, 2025
Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinomaWunan Mi, Antonio Cigliano, Grazia Galleri, et al.
Cancer Cell|August 2, 2016
Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma DevelopmentJessica Endig, Laura Elisa Buitrago-Molina, Silke Marhenke, et al.
The Lancet Regional Health. Europe|March 17, 2025
Mapping the landscape of biliary tract cancer in Europe: challenges and controversiesLorenza Rimassa, Shahid Khan, Bas Groot Koerkamp, et al.
Hepatology (Baltimore, Md.)|January 26, 2026
Stroma-driven inter- and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluationAnna Saborowski, Simon Peters, Jinbo Zhao, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Hepatology Communications|March 13, 2019
Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer <i>In</i> <i>Vivo</i> and <i>In Vitro</i>Anna Saborowski, Katharina Wolff, Steffi Spielberg, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2026
Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 studyArndt Vogel, Najib Ben Khaled, Javier Ruiz Ramirez, et al.
Therapeutic Advances in Medical Oncology|March 7, 2022
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experienceTiago de Castro, Leonie S Jochheim, Melanie Bathon, et al.
Clinical Transplantation|May 19, 2026
A Retrospective Multicenter Study Identifies a Similar Overall Survival of Patients After Liver Transplantation With Incidental Cholangiocarcinoma Compared to Hepatocellular CarcinomaSophia Heinrich, Alejandro Campos-Murguia, Angelina Mensah, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trialArndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
Gut|November 27, 2019
Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cellsZhen Dai, Guangqi Song, Asha Balakrishnan, et al.
JHEP Reports : Innovation in Hepatology|June 18, 2025
Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinomaWunan Mi, Antonio Cigliano, Grazia Galleri, et al.
Cancer Cell|August 2, 2016
Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma DevelopmentJessica Endig, Laura Elisa Buitrago-Molina, Silke Marhenke, et al.
The Lancet Regional Health. Europe|March 17, 2025
Mapping the landscape of biliary tract cancer in Europe: challenges and controversiesLorenza Rimassa, Shahid Khan, Bas Groot Koerkamp, et al.
Hepatology (Baltimore, Md.)|January 26, 2026
Stroma-driven inter- and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluationAnna Saborowski, Simon Peters, Jinbo Zhao, et al.
Pageof 8